A recent Government Account¬ability Office report found that direct-to-consumer prescription-drug advertising may be a major factor contributing to rising spending on medications by the Medicare program and its beneficiaries.
In this article, we discuss the results of a recent rigorously conducted study showing that therapy with the thyroid-hormone drug levothyroxine in older adults with subclinical hypo-thyroidism (a mild form of underactive thyroid) who had depressive symptoms provided no significant benefit.
Unfounded claims about the supportive roles of vitamin C and zinc for treating COVID-19 infection have led to increased demand and expenditures for these supplements, among others. Evidence from a recent study that was conducted by Cleveland Clinic researchers refutes these claims.
In his editor’s column, Dr. Michael Carome discusses why the FDA’s June approval of Biogen’s monoclonal-antibody drug aducanumab (ADUHELM) for the treatment of Alzheimer’s disease was one of the worst decisions in the agency’s history.
Patients taking the widely prescribed calcium channel blocker nifedipine (PROCARDIA, PROCARDIA XL) should be aware that it has clinically important interactions with many other prescription medications.
In this article, we discuss an important new warning issued by the FDA about preliminary results from a safety clinical trial that showed increased risks of serious heart-related adverse effects and cancer in rheumatoid arthritis patients taking the oral drug tofacitinib.
Learn why tianeptine — an addictive synthetic chemical compound that has led to abuse, physical dependence and withdrawal adverse reactions similar to those of opioids — has emerged as a growing public health threat in the U.S. and internationally.